Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: Scientific Problem State

Drapkina, О. М.; Yafarova, A. A.

doi:10.20996/1819-6446-2017-13-5-645-650

Cited by 12 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also important to remember that cardiovascular mortality is the main cause of death in NAFLD. In our model, cardiovascular mortality is 1.7 times higher than liver mortality for the entire cohort, as both NAFLD and T2DM increase the risk of major adverse cardiac events (11)(12)(13)24,40). In contrast, NASH with T2DM also accounts for a large number of liver-related adverse outcomes, which is primarily limited to the progressive NASH.…”

Section: Discussionmentioning

confidence: 97%

“…[5][6].45% in the general population (8,9). Patients with NASH are more likely to progress to advanced liver disease and die of liver-related causes, and all NAFLD patients, regardless of underlying liver pathology, are at risk for cardiovascular disease (10)(11)(12)(13). In addition to clinical burden, NAFLD and NASH are associated with significant health care utilization (14)(15)(16).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.

et al. 2019

View full text Add to dashboard Cite

Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) and is strongly associated with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NASH have increased risk for adverse clinical outcomes, leading to higher risk for mortality and morbidity. We built a Markov model with 1-year cycles and 20-year horizon to estimate the economic burden of NASH with T2DM in the U.S. RESEARCH DESIGN AND METHODS Cohort size was determined by population size, prevalence of T2DM, and prevalence and incidence of NASH in 2017. The model includes 10 health statesdNAFL, NASH fibrosis stages F0 through F3, compensated and decompensated cirrhosis, hepatocellular carcinoma, 1 year post-liver transplant, and post-liver transplantdas well as liver-related, cardiovascular, and background mortality. Transition probabilities were calculated from meta-analyses and literature. Annual costs for NASH and T2DM were taken from literature and billing codes. RESULTS We estimated that there were 18.2 million people in the U.S. living with T2DM and NAFLD, of which 6.4 million had NASH. Twenty-year costs for NAFLD in these patients were $55.8 billion. Over the next 20 years, NASH with T2DM will account for 65,000 transplants, 1.37 million cardiovascular-related deaths, and 812,000 liver-related deaths. CONCLUSIONS This model predicts significant clinical and economic burden due to NASH with T2DM over the next 20 years. In fact, this burden may be greater since we assumed conservative inputs for our model and did not increase costs or the incidence of T2DM over time. It is highly likely that interventions reducing morbidity and mortality in NASH patients with T2DM could potentially reduce this projected clinical and economic burden. Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis (.5%) in the absence of excessive alcohol consumption or other causes of fatty liver disease and chronic liver disease (1). NAFLD ranges from simple steatosis (NAFL), which has a low likelihood of progression to advanced liver disease, to nonalcoholic steatohepatitis (NASH), which has greater potential for progression. NAFLD is recognized as one of the most common causes of chronic liver disease in the U.S. and worldwide (1-3). NAFLD is

show abstract

Section: Discussionmentioning

confidence: 97%

mentioning

confidence: 99%

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.

et al. 2019

View full text Add to dashboard Cite

show abstract

“…15 Patients with NASH are more likely to move to advanced liver disease, die of hepatic illness and are at risk of cardiovascular disease in all NAFLD patients irrespective of underlying liver pathology. 15,16 Nonalcoholic fatty liver disease and NASH are associated with significant health care use in addition to clinical burden. 17 In the present study, 68 (56.67%) were males and 52(43.33%) were females with mean age was 45.74±10.54 years.…”

Section: Discussionmentioning

confidence: 99%

Proportion of Nonalcoholic Steatohepatitis in Patients with Chronic Liver Disease

Abro¹,

Shaikh²,

Mugheri³

et al. 2021

PJMHS

View full text Add to dashboard Cite

Aim: To determine the frequency of nonalcoholic steatohepatitis in patients with liver cirrhosis. Study Design: Retrospective/observational Place and Duration of Study: Department of Medicine, Chandka Medical College Hospital, Larkana from 1st July 2020 to 31st March 2021. Methodology: One hundred and twenty patients of both genders presented with liver cirrhosis were enrolled in this study. Patient’s detailed demographics including age, sex, body mass index, smoking status, alcohol consumption and family history of liver disease were recorded after taking written informed consent. Laboratory examination was done to examine the proportion of hepatitis B virus, hepatitis C virus and nonalcoholic steatohepatitis. Results: There were 68 (56.67%) males and 52 (43.33%) were females with mean age 45.74±10.54 years. Among all the patients hepatitis C virus was found in 62 (51.67%) patients, 15 (12.5%) had hepatitis B virus, 17 (14.17%) had hepatitis B virus + hepatitis C virus and nonalcoholic steatohepatitis was found in 26 (21.67%) patients. Conclusion: Nonalcoholic steatohepatitis was the major cause of liver cirrhosis in Pakistani population. The proportion of NASH in liver cirrhosis patients was 21.67%. Keywords: Nonalcoholic steatohepatitis (NASH), Liver Cirrhosis, Hepatitis B virus, Hepatitis C virus

show abstract

“…В норме эпикардиальный жир поглощает свободные жирные кислоты из кровеносного русла, которые могут быть использованы кардиомиоцитами в качестве дополнительного источника энергии [31]. При избыточном их накоплении наблюдается повышение риска развития ССЗ [41], в частности фибрилляции предсердий [8,14].…”

Section: особенности патогенеза нажбп в контексте кардиоваскулярной коморбидностиunclassified

Cardiovascular comorbidity in non-alcoholic fatty liver disease

Тимакова¹,

Скирденко²,

Ливзан³

et al. 2020

jour

View full text Add to dashboard Cite

Актуальной проблемой современной медицины является поиск связей между неалкогольной жировой болезнью печени и сердечно-сосудистыми заболеваниями. Реальная клиническая практика нуждается в углублении знаний о взаимном влиянии этих патологий и разработке алгоритмов сопровождения таких коморбидных пациентов.В обзоре актуальной литературы показаны данные об увеличении кардиоваскулярных рисков и ускорении прогрессирования патологии печени при сочетании неалкогольной жировой болезни печени и сердечно-сосудистых заболеваний. В статье описаны звенья патогенеза неалкогольной жировой болезни печени, оказывающие влияние на развитие сердечно-сосудистых заболеваний (инсулинорезистентность, гипоадипонектинемия, гиперлептинемия, нарушения липидного обмена, активация воспаления и др.). Продемонстрирована роль воспаления, гормональных изменений и влияние кишечной микробиоты на течение обоих заболеваний. В обзоре представлены данные о влиянии общих факторов риска (нарушение липидного обмена, нарушение углеводного обмена, ожирение и др.) на течение обеих патологий. Приведены данные литературы о связи неалкогольной жировой болезни печени с развитием артериальной гипертензии (прежде всего за счет увеличения жесткости сосудистой стенки), ишемической болезнью Тимакова Арина Юрьевна, студент 4 курса лечебного факультета Скирденко Юлия Петровна, ассистент кафедры факультетской терапии, профессиональных болезней, кандидат медицинский наук Ливзан Мария Анатольевна, ректор, заведующий кафедрой факультетской терапии, профессиональных болезней, профессор, д. м. н. Кролевец Татьяна Сергеевна, ассистент кафедры факультетской терапии, профессиональных болезней, кандидат медицинский наук Николаев Николай Анатольевич, профессор кафедры факультетской терапии, профессиональных болезней, доцент, д. м. н. Нелидова Анастасия Владимировна, доцент кафедры пропедевтики внутренних болезней, доцент, кандидат медицинский наук Arina Yu. Timakova, medical faculty, student

show abstract

Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: Scientific Problem State

Cited by 12 publications

References 33 publications

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.

Proportion of Nonalcoholic Steatohepatitis in Patients with Chronic Liver Disease

Cardiovascular comorbidity in non-alcoholic fatty liver disease

Contact Info

Product

Resources

About